Corrixr Taps Seagen Veteran to Steer Gene-Editing Cancer Therapy to Clinic

NEWARK, DE – July 15, 2026 – For a pre-clinical biotech company, every leadership change is scrutinized. But when the new appointee is a seasoned drug developer with a multi-billion-dollar track record, it’s not just a personnel update—it’s a declaration of intent. Corrixr Therapeutics, a genetic medicine company spun out of ChristianaCare’s Gene Editing Institute, has made such a declaration by appointing Nancy Whiting, PharmD, as its new Chair of the Board.

The move comes as Corrixr stands at a critical inflection point, preparing to advance its lead candidate, CXR101, from the laboratory bench toward its first-in-human clinical trials. Dr. Whiting, a 15-year veteran of Seagen, steps into the role at a moment when Corrixr needs more than just scientific brilliance; it needs a navigator with a map to the market. This appointment signals a deliberate and strategic pivot, focusing the company’s resources on the complex journey from prototype to profit.

A Veteran Navigator for the Clinical Gauntlet

Dr. Whiting is not just another executive. Her career is a testament to shepherding complex oncology drugs through the treacherous waters of late-stage development, regulatory approval, and commercial launch. During her tenure at Seagen, she was instrumental in the success of a portfolio of transformative cancer therapies, including ADCETRIS, PADCEV, TUKYSA, and TIVDAK. These are not minor footnotes; they are major products that have reshaped treatment paradigms in lymphoma, bladder, breast, and cervical cancers, respectively.

"Nancy’s appointment as Board Chair, strengthens Corrixr’s leadership at a pivotal moment as we advance toward the clinic,” said Hilary M. Malone, Ph.D., Chief Executive Officer of Corrixr. This sentiment is echoed by the outgoing chair, Dr. Janice E. Nevin, who noted that Dr. Whiting brings the “extensive oncology development and commercial experience Corrixr needs as it moves toward the clinic.”

For investors and industry watchers, this is a significant de-risking event. Bringing a drug to market is a gauntlet of IND filings, trial design, FDA negotiations, and strategic commercial planning. Dr. Whiting has run this gauntlet successfully multiple times. Her experience complements Corrixr’s deep scientific foundation, creating a leadership team equipped for the company’s next chapter.

“Having spent my career bringing transformative oncology medicines through development and into the hands of patients, I see that same potential with Corrixr,” Dr. Whiting stated, underscoring her belief in the company's platform. Her current role as CEO of Recludix Pharma and board positions at Caribou Biosciences and Boundless Bio further cement her status as a central figure in modern oncology development.

Rewriting the Code of Cancer Resistance

At the heart of Corrixr’s potential is its groundbreaking science. The company is tackling some of the world's most aggressive and treatment-resistant cancers: squamous cell carcinomas (SCCs) of the lung, head & neck, and esophagus. These malignancies are notoriously difficult to treat, often developing resistance to chemotherapy and radiation, leading to poor patient outcomes.

Corrixr's lead program, CXR101, takes a novel approach. Instead of a conventional small molecule, it uses a proprietary CRISPR-based gene editing system to go after the root of the problem: a transcription factor called NRF2. In healthy cells, NRF2 is a protective stress responder. In many squamous tumors, it is perpetually hyperactive, acting as a master switch that fuels tumor survival, proliferation, and resistance to therapy. For years, NRF2 has been considered an “undruggable” target.

CXR101 is designed to do what small molecules cannot: eliminate NRF2 directly at its genetic source. The therapy is delivered locally to the tumor using lipid nanoparticles (LNPs), aiming to disrupt the NRF2 gene within cancer cells. The result, as shown in robust pre-clinical studies published in Molecular Therapy Oncology, is profound. By knocking out NRF2, CXR101 effectively collapses the tumor's defenses, resensitizing it to standard-of-care chemotherapies.

This strategy is a paradigm shift. It doesn't necessarily replace chemotherapy but aims to make it work again, even in patients who have become resistant. The potential benefits are manifold: improving outcomes for non-responders, potentially allowing for lower and less toxic chemotherapy doses, and broadening the patient population that can benefit from existing treatments. The company is also exploring an inhaled version of the therapy for lung cancer, highlighting a focus on innovative delivery to maximize efficacy and minimize systemic toxicity.

The Bedrock of a Bench-to-Bedside Partnership

Corrixr’s story is incomplete without understanding its unique relationship with ChristianaCare. The company was spun out of the health system’s Gene Editing Institute (GEI) in 2022, born from a decade of foundational research. This structure provides Corrixr with what its leadership calls an “unmatched research and development engine” and a direct line of sight into the clinical environment.

This is not a typical venture capital-backed startup. It is the commercial-facing arm of a deep, integrated research program within a major healthcare provider. This bench-to-bedside model ensures that the science is always grounded in real-world clinical challenges and patient needs.

The recent leadership transition at ChristianaCare further solidifies this bond. Dr. Janice Nevin, who is retiring as CEO of ChristianaCare, will remain on Corrixr’s board, ensuring continuity of vision. Her successor, Jenn Schwartz, will also join the board. This dual presence of both the outgoing and incoming CEOs of Corrixr's founding institutional partner sends a powerful message of unwavering long-term support.

“It has been an honor to chair Corrixr’s board as ChristianaCare’s founding institutional investor and partner, and to help guide the company from its origins at the Gene Editing Institute to this point,” Dr. Nevin commented. Her continued presence, alongside Ms. Schwartz, ensures the strategic alignment between the research institute, the health system, and the commercial entity remains intact.

With Dr. Whiting now at the helm of the board, Corrixr has assembled a powerful triumvirate: groundbreaking science from the GEI, stable institutional and clinical backing from ChristianaCare, and now, world-class commercialization expertise. While the path to an approved therapy is never guaranteed, Corrixr is strategically positioning itself with the leadership and foundation necessary to turn a promising prototype into a profitable, life-saving medicine.